…
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -256.25M | -284.12M | -226.99M | -147.72M | -155.13M |
| Net income | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M |
| Selling general administrative | 358.78M | 272.61M | 186.36M | 64.95M | 30.10M |
| Gross profit | 228.69M | 73.67M | 20.64M | 0.06M | -132.17M |
| Reconciled depreciation | 0.66M | 0.53M | 0.53M | 0.48M | 0.37M |
| Ebit | -264.28M | -286.22M | -231.76M | -154.49M | -162.64M |
| Ebitda | -263.63M | -285.69M | -231.23M | -154.01M | -162.27M |
| Depreciation and amortization | 0.66M | 0.53M | 0.53M | 0.48M | 0.37M |
| Non operating income net other | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M |
| Operating income | -263.63M | -285.69M | -231.23M | -154.01M | -162.27M |
| Other operating expenses | 512.76M | 367.40M | 253.76M | 154.07M | 162.27M |
| Interest expense | 7.38M | 2.10M | 4.76M | 6.77M | 0.00M |
| Tax provision | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M |
| Interest income | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M |
| Net interest income | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M |
| Income tax expense | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M |
| Total revenue | 249.13M | 81.71M | 22.53M | 0.06M | 0.00M |
| Total operating expenses | 492.31M | 359.36M | 251.86M | 154.07M | 162.27M |
| Cost of revenue | 20.44M | 8.03M | 1.90M | 89.12M | 132.17M |
| Total other income expense net | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M |
| Net income from continuing ops | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M |
| Net income applicable to common shares | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 728.29M | 754.78M | 489.92M | 717.31M | 251.19M |
| Other current assets | 42.44M | 45.19M | 26.84M | 15.64M | 6.31M |
| Total liab | 136.87M | 98.71M | 72.03M | 60.45M | 56.18M |
| Total stockholder equity | 591.42M | 656.07M | 417.89M | 656.86M | 195.01M |
| Other current liab | 108.48M | 68.27M | 37.93M | 25.81M | 25.61M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -1617.16M | -1477.49M | -1221.23M | -937.10M | -710.10M |
| Other assets | - | 0.09M | 0.09M | 0.09M | 0.35M |
| Cash | 147.77M | 148.62M | 92.36M | 60.05M | 107.64M |
| Total current liabilities | 123.55M | 83.24M | 53.36M | 36.85M | 36.22M |
| Net debt | -130.83M | -128.57M | -66.96M | -30.90M | -84.49M |
| Short term debt | 3.61M | 4.57M | 6.73M | 5.54M | 3.19M |
| Short long term debt total | 16.94M | 20.04M | 25.41M | 29.14M | 23.14M |
| Other stockholder equity | 2208.47M | 2137.74M | 1639.48M | 1593.48M | 904.97M |
| Property plant equipment | - | 1.91M | 22.56M | 2.00M | 2.26M |
| Total current assets | 667.80M | 737.96M | 467.28M | 690.90M | 230.32M |
| Net tangible assets | - | 656.07M | 417.89M | 656.86M | 195.01M |
| Short term investments | 350.17M | 443.29M | 319.97M | 597.40M | 116.37M |
| Net receivables | 114.02M | 75.19M | 20.16M | 10.76M | 0.35M |
| Inventory | 11.65M | 23.92M | 7.95M | 7.06M | - |
| Accounts payable | 11.45M | 10.39M | 8.69M | 5.50M | 7.43M |
| Accumulated other comprehensive income | 0.10M | -4.19M | -0.36M | 0.48M | 0.13M |
| Common stock total equity | - | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings total equity | - | -1477.49M | -1221.23M | -937.10M | -710.10M |
| Non currrent assets other | 45.91M | 0.09M | 0.09M | 0.09M | 0.09M |
| Non current assets total | 60.50M | 16.82M | 22.64M | 26.41M | 20.86M |
| Capital lease obligations | 16.94M | 20.04M | 25.41M | 29.14M | 23.14M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -127.59M | 280.67M | -480.03M | 178.14M | 135.03M |
| Change to liabilities | 12.39M | 3.19M | -1.73M | -3.21M | 22.17M |
| Total cashflows from investing activities | -128.37M | 280.34M | -480.30M | 177.44M | 134.64M |
| Total cash from financing activities | 455.16M | 11.52M | 664.18M | 3.24M | 0.69M |
| Change to operating activities | 11.16M | 0.74M | -7.80M | 5.68M | 11.63M |
| Net income | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M |
| Change in cash | 56.60M | 32.32M | -46.19M | 52.69M | 17.16M |
| Begin period cash flow | 93.77M | 61.45M | 107.64M | 54.95M | 37.79M |
| End period cash flow | 150.37M | 93.76M | 61.45M | 107.64M | 54.95M |
| Total cash from operating activities | -270.19M | -259.54M | -230.07M | -127.98M | -118.17M |
| Issuance of capital stock | 433.72M | 0.00M | 652.71M | 0.00M | 0.00M |
| Depreciation | 0.66M | 0.53M | 0.53M | 0.48M | 0.37M |
| Other cashflows from investing activities | - | - | - | 178.14M | 135.03M |
| Change to inventory | -15.97M | -0.89M | -7.06M | -7.06M | -7.06M |
| Change to account receivables | -55.03M | -9.39M | -10.76M | -10.76M | -10.76M |
| Sale purchase of stock | 455.16M | 11.52M | 664.18M | 3.24M | 0.69M |
| Other cashflows from financing activities | 21.44M | 11.52M | 11.46M | 3.24M | 0.69M |
| Change to netincome | 43.10M | 30.40M | 24.59M | 21.25M | 18.12M |
| Capital expenditures | 0.78M | 0.33M | 0.27M | 0.70M | 0.39M |
| Change receivables | -55.03M | -9.39M | -10.76M | - | - |
| Cash flows other operating | 0.48M | -11.38M | -7.99M | 2.35M | -2.76M |
| Cash and cash equivalents changes | 56.60M | 32.32M | -46.19M | 52.69M | 17.16M |
| Change in working capital | -58.14M | -6.35M | -27.28M | -0.59M | 19.94M |
| Stock based compensation | 43.01M | 34.30M | 24.12M | 20.79M | 17.40M |
| Other non cash items | 0.54M | 0.18M | 0.21M | 0.19M | -529.97M |
| Free cash flow | -270.96M | -259.87M | -230.34M | -128.68M | -118.56M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MKKGY Merck KGaA ADR |
0.45 1.38% |
33.07 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
170.05 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.31 1.47% |
21.43 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.72 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
430 East 29th Street, New York, NY, United States, 10016
646 440 9333
610
| Name | Title | Year Born |
|---|---|---|
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman, CEO & Pres | 1953 |
| Mr. Lawrence J. Hineline CPA, CPA | Sr. VP of Fin., CFO, Treasurer & Assistant Sec. | 1956 |
| Mr. Michael I. Halstead J.D. | Exec. VP, Gen. Counsel & Sec. | 1973 |
| Dr. Suresh K. Durgam M.D. | Exec. VP & Chief Medical Officer | 1969 |
| Mr. Mark Neumann | EVP & Chief Commercial Officer | 1963 |
| Dr. Robert E. Davis Ph.D. | Sr. VP & Chief Scientific Officer | 1951 |
| Mr. Juan Fernando Sanchez | VP of Corp. Communications & Investor Relations | 1971 |
| Ms. Karen Patruno Sheehy Esq. | Sr. VP & Chief Compliance Officer | 1962 |
| Dr. Michael Olchaskey | Sr. VP & Head of Regulatory Affairs | NA |
| Mr. John A. Bardi | Sr. VP of Market Access, Policy & Gov. Affairs | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.